The UC San Francisco Department of Radiology and Biomedical Imaging is pleased to announce that Nola Hylton, PhD is a 2022 International Society for Magnetic Resonance in Medicine (ISMRM) Gold Medal recipient for her foundational work in breast MR imaging.
OncLive®, the nation’s leading multimedia resource for oncology professionals, has named Dr. Eric Small among the winners of their 10th annual Giants of Cancer Care® awards.
Patients diagnosed with a type of brain tumor survived for longer when they were treated aggressively with surgery, radiation and chemotherapy. But far from suggesting that more treatment always leads to better survival, the study by UC San Francisco underscores the critical role of genomic profiling in diagnosing and grading brain tumors.
Fostering a diverse workforce poses enormous challenges and requires introspection and culture change. Newly appointed Associate Director for Diversity, Equity, and Inclusion Dr. Tung Nguyen says better results happen through intention and collaboration.
Mitchel Berger, MD, neurosurgeon and director of the UCSF Brain Tumor Center, discusses how precision medicine and other breakthroughs in brain tumor treatment at UCSF contribute to the Cancer Moonshot’s goal of ending cancer as we know it.
At the annual meeting of the American Association for Cancer Research (AACR), UCSF scientists and trainees lent their expertise of the latest discoveries across the spectrum of cancer research—from population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy.
Cancer therapies have increased the survival of cancer patients, however certain cancer treatments can damage the heart and the cardiovascular system. In the latest CureTalks podcast, UCSFʻs Dr. Javid Moslehi discusses the nuances of what cardio-oncology care and management of patients whose cardiovascular health has been affected by cancer entails.
Krishna Komanduri, MD, an international leader in the fields of hematology-oncology, transplantation, and cellular immunotherapy, has been named chief of the Division of Hematology-Oncology at UCSF Health, physician-in-chief of the Helen Diller Family Comprehensive Cancer Center (HDFCCC) and clinical director of the UCSF Living Therapeutics Initiative.
Researchers at UC San Francisco have successfully leveraged an FDA-approved drug to halt growth of tumors driven by mutations in the RAS gene, which are famously difficult to treat and account for about one in four cancer deaths.
CureTalks discusses the rising incidence of colorectal cancer occurring in adults younger than age 50, risk factors, symptoms, treatments with Dr. Michael Potter and Dr. Ma Somsouk from UCSF Helen Diller Family Comprehensive Cancer Center, and patient advocates Curt Pesmen and Danielle Ripley-Burgess.